TORONTO, Sept. 15, 2021 (GLOBE NEWSWIRE) — Novamind Inc. (CSE:NM, OTCQB:NVMDF, FSE: HN2)) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Life Sciences Investor Forum, taking place virtually on Thursday, September 16 at 12:00 PM EST.
Join Novamind’s Chief Medical Officer and Director, Dr. Reid Robison, live as he presents the Company’s model for scaling access to psychedelic medicine through a multi-state, U.S. expansion of leading psychiatry clinics and clinical research sites. Investors are invited to participate in an open Q&A session following the presentation.
An archived webcast will be made available for attendees who are not able to join the event live.
Click here to join the webcast.
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
Contact Information Novamind Yaron Conforti, CEO and Director Telephone: +1 (647) 953 9512 Samantha DeLenardo, VP, Communications Email: firstname.lastname@example.org Bill Mitoulas, Investor Relations Email: email@example.com